Researchers have developed a stem cell-based model of the human intestine that may transform how new IBD treatments are ...

Scientists recently discovered that glycyrrhizin, a substance taken from black licorice root, may reduce inflammation and ...

Targeted dietary therapies can induce remission in 50%-80% of IBD patients; discover which protocols — EEN, CDED, and whole ...

INFLAMMATORY Bowel Disease is a term for a group of chronic, lifelong disorders characterised by systemic immune dysfunction ...

Many people with Crohn’s disease and ulcerative colitis experience joint pain, leading researchers to believe there’s a link between the gut and the joints.

Patients with obesity and inflammatory bowel disease showed improved bowel function while receiving GLP-1 receptor agonists ...

Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD ...

IBD is an immune condition. Instead of peacefully coexisting with gut microbes, the immune system becomes overly reactive, ...

For too long you have suffered from inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). Crohn’s disease.

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Investigational New Drug (IND) application for 9MW5211, its ...

What is IBD: IBD is a chronic inflammatory condition of the digestive tract, with Crohn’s disease and ulcerative colitis as its main forms, each affecting different areas and requiring tailored care.

Pharmaceutical Technology rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.